Paraneoplastic syndromes review: The great forgotten ones.
Dermatology
Endocrinology
Hematology
Neurology
Paraneoplastic
Review
Screening
Treatment
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
30
10
2021
revised:
14
03
2022
accepted:
31
03
2022
pubmed:
5
4
2022
medline:
27
5
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Paraneoplastic syndromes (PNS) are a group of disorders that can affect the oncologic patient, and which are not directly attributable to tumour invasion, tumour compression or metastasis. In fact, they are due to tumour secretion of functional hormones or peptides or are related to immune cross-reactivity with the host tissue. These syndromes are called paraneoplastic because the components that cause them do not derive from the organ or tissue of origin, but from the neoplasm suffered by the patient. It is estimated that 10-15% of people with cancer suffer from a PNS (Coleman, 2018). PNS is the second direct cause of death (27% of cases) in cancer patients, after cancer itself. Consequently, it is of remarkable importance to recognize and treat SPNs specifically (Serraj et al., 2020). In view of the above, the aim of this article is to review the state of the art in neurological, haematological, endocrine, and dermatological paraneoplastic syndromes. It is a review in which the most relevant PNS and their symptomatology are described, inquiring into their diagnosis and treatment.
Identifiants
pubmed: 35378267
pii: S1040-8428(22)00100-7
doi: 10.1016/j.critrevonc.2022.103676
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103676Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.